Clinical Trial Detail

NCT ID NCT03225547
Title Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Chicago

Her2-receptor negative breast cancer

triple-receptor negative breast cancer


Mifepristone + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST